Can 68 Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study-Reference-Cited by-同舟云学术

Can 68 Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study

Published:2021-04 Issue:4 Volume:205 Page:1082-1089
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Chen Mengxia¹²,Zhuang Junlong¹²,Fu Yao³,Guo Suhan²,Zang Shiming⁴,Ai Shuyue⁴,Qiu Xuefeng¹²,Wang Feng⁴,Guo Hongqian¹²

Affiliation:

1. Department of Urology, Affiliated Drum Tower hospital, Medical School of Nanjing University, Nanjing, China

2. Institute of Urology, Nanjing University, Nanjing, China

3. Department of Pathology, Affiliated Drum Tower hospital, Medical School of Nanjing University, Nanjing, China

4. Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment and Staging Intensification Strategies Associated with Radical Prostatectomy for High-Risk Prostate Cancer: Efficacy Evaluation and Exploration of Novel Approaches;Cancers;2024-07-05

2. The role of androgen deprivation therapy prior to radical prostatectomy in high-risk prostate cancer: a systematic review;Minerva Urology and Nephrology;2024-05

3. Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects;BMC Cancer;2024-04-11

4. The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy;Urologic Oncology: Seminars and Original Investigations;2024-03

5. The Association Between [⁶⁸Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy;Journal of Nuclear Medicine;2023-07-20